As a result of the drug makers’ failure to adequately warn
about the risks associated with the anticoagulant, financial compensation may
be available through a Xarelto lawsuit for individuals who have experienced:
- Internal Bleeding or Gastrointestinal Bleeding
- Brain Hemorrhage
- Hemorrhagic Stroke
- Wrongful Death from Bleeding Problems
To review whether you, a friend or family member may have a
Xarelto case against the drug makers, request a free consultation today.
Xarelto Bleeding Problems
Xarelto was introduced in 2011, as a joint product developed
by Johnson & Johnson’s Janssen Pharmaceuticals subsidiary and Bayer Health
Care.
The anticoagulant has been used by millions of Americans to
reduce the risk of stroke, deep vein thrombosis, pulmonary embolism and other
blood clot injuries. It has been prescribed to individuals with non-valvular
atrial fibrillation, following knee and hip replacement surgery and to prevent
recurrence of clots.
While all blood thinners carry a risk of internal bleeding,
Xarelto appears to be associated with a much greater risk than the
manufacturers indicated in warnings provided for consumers and the medical
community.
In many cases, Xarelto bleeding problems cannot be
controlled by physicians, due to the lack of an approved reversal agent.
Johnson & Johnson and Bayer promoted Xarelto as a
superior alternative to warfarin, which has been the go-to anticoagulation
therapy for decades.
Although the manufacturers have indicated that the newer
drug requires less frequent monitoring than warfarin, increasing evidence
suggests that blood monitoring on Xarelto may reduce the bleeding risk. In
addition, it appears that information was withheld about the lack of an
effective Xarelto reversal agent to stop bleeding problems that may develop.
While doctors are able to reverse the effects of warfarin
quickly if bleeding occurs, Xarelto bleeding is often uncontrollable, increasing
the risk of serious injury or death.
Xarelto warnings fail to properly address the increased risk
for these serious and fatal bleeding problems, despite a substantial number of
adverse event reports and other findings suggesting that individuals taking
Xarelto have more gastrointestinal bleeds and need more transfusions.
In addition to the inadequate warnings, Xarelto does not
appear to provide sufficient benefits to justify the additional risks.
Therefore, many lawsuits allege that a Xarelto recall should be issued,
claiming that the medication is unreasonably dangerous and defective without an
effective reversal agent.
Allegations in Lawsuits over Xarelto
Claims raised in the Xarelto litigation are similar to many
of the allegations brought against Boehringer Ingelheim over their related
anticoagulant, Pradaxa.
Following the filing of thousands of lawsuits over failure
to warn about the risk of bleeding problems with Pradaxa, Boehringer Ingelheim
agreed to pay more than $650 million in mid-2014 to resolve the litigation.
Similar compensation may be available through Xarelto settlements, as it
appears that Bayer and Johnson & Johnson also withheld important safety
information about their drug.
Among the allegations raised in Xarelto injury lawsuits
being pursued by individuals nationwide, plaintiffs claim Johnson & Johnson
and Bayer:
- Failed to provide accurate warnings about the risk of Xarelto bleeds;
- Withheld information about the lack of an effective Xarelto reversal agent;
- Engaged in aggressive marketing that encouraged doctors to use the more expensive and more dangerous drug;
- Sold an unreasonably dangerous and defective drug as it was initially formulated;
- Failed to update warnings, issue a “Dear Doctor” letter or issue a Xarelto recall after it became clear that a large number of users were suffering severe and life-threatening injuries from uncontrollable bleeding.
Rather than withdrawing Xarelto from the market or taking
steps to ensure accurate information was provided for consumers and the medical
community, Johnson & Johnson and Bayer continued to promote the medication
as safe and effective, causing millions of additional Americans to be exposed
to a risk of serious injury.
The lawyers at Chhabra & Gibbs, P.A. are reviewing
individual bleeding injury claims and potential Xarelto class action lawsuits
against Johnson & Johnson and Bayer.
The makers of Xarelto appear to have placed their desire for
profits before consumer’s safety, by failing to properly research the risk of
bleeds on Xarelto or provide adequate information about the serious and
potentially life-threatening health problems that may be caused by use of
Xarelto.
For families of individuals who died as a result of these
bleeding problems, damages may be available through a Xarelto wrongful death
lawsuit.
The drug makers stand to generate substantial profits due to
their decision to provide inaccurate and incomplete warnings. Xarelto has been
estimated to be the 19th best-selling drug in the world by 2018, with sales
expected to reach $3.7 billion per year.
Rather than allowing the drug makers to benefit from this
behavior, lawsuits over Xarelto bleeding problems seek to hold the
pharmaceutical companies responsible for injuries suffered by former users. In
addition, pursuing Xarelto litigation may also prevent similar behavior in the
drug industry.
If you or a loved one have been affected by the drug Xarelto,
contact Chhabra & Gibbs, P.A. today for a free consultation by going to our
website at http://www.cglawms.com or
calling 601-948-8005.
Very nice article about Xarelto Leads to Bleeding Injury or Death.We are giving some services about this you can take it form United states Xarelto lawsuit Xarelto side effects Xarelto attorney
ReplyDelete